Anxiety and Related Sleep Disorders - LATAM

Revenue in the Anxiety and Related Sleep Disorders market is projected to reach US$602.00m in 2024.
Revenue is expected to show an annual growth rate (CAGR 2024-2029) of -1.54%, resulting in a market volume of US$557.00m by 2029.
In global comparison, most revenue will be generated United States (US$3.21bn in 2024).
In relation to total population figures, per person revenues of US$13.36 are generated in 2024.

The Anxiety and Related Sleep Disorders market covers sales of three drug classes: anxiolytics, hypnotics, and sedatives. These classes contain different types of drugs, such as benzodiazepines, anticonvulsants, and antihistamines, that reduce anxiety and insomnia symptoms caused by anxiety. These medications mainly fall into the category of prescription drugs.

Market values represent the revenues generated by manufacturers and are based on retail prices for each drug category including all drugs, regardless of whether they are reimbursed or not.

Company examples: Pfizer, Bristol-Myers Squibb, GlaxoSmithKline PLC, Johnson & Johnson, and Merck & Co.

Pharmaceutical sales and consumption of anxiolytics
Pharmaceutical sales and consumption hypnotics and sedatives

Non-mental health related sleep disorders
Any other anxiety medications
Psychotherapy

The Anxiety and Related Sleep Disorders market in LATAM is experiencing significant growth and development due to changing customer preferences, emerging trends in the market, local special circumstances, and underlying macroeconomic factors.Customer preferences in the LATAM region have shifted towards a greater focus on mental health and well-being. As awareness about anxiety and related sleep disorders increases, more people are seeking treatment and management options. This has led to a higher demand for pharmaceutical products, therapy services, and alternative treatment methods.In terms of trends, the market in LATAM is witnessing a rise in the use of digital health solutions for anxiety and related sleep disorders. Mobile applications, online therapy platforms, and wearable devices are becoming popular tools for self-management and monitoring. This trend is driven by the increasing availability of smartphones and internet connectivity in the region, as well as the convenience and accessibility these digital solutions offer.Another trend in the market is the growing interest in natural and herbal remedies for anxiety and sleep disorders. Consumers in LATAM are increasingly seeking alternative treatment options that have fewer side effects and are perceived as more holistic. This has created opportunities for companies that specialize in herbal supplements, aromatherapy products, and other natural remedies.Local special circumstances in LATAM also contribute to the development of the Anxiety and Related Sleep Disorders market. The region has a high prevalence of mental health issues, including anxiety and sleep disorders, which creates a large potential customer base. Additionally, cultural factors such as a strong emphasis on family and community support can influence the way these disorders are perceived and managed. This provides opportunities for localized marketing and tailored solutions that take into account the unique needs and preferences of the LATAM population.Underlying macroeconomic factors play a role in the growth of the Anxiety and Related Sleep Disorders market in LATAM. Economic growth and increasing disposable income levels in the region have led to a higher affordability of healthcare products and services. This, combined with improvements in healthcare infrastructure and access, has made it easier for individuals to seek and receive treatment for anxiety and sleep disorders.In conclusion, the Anxiety and Related Sleep Disorders market in LATAM is developing due to changing customer preferences, emerging trends, local special circumstances, and underlying macroeconomic factors. As the region continues to prioritize mental health and well-being, the market is expected to experience further growth and innovation in the coming years.

Data coverage:

Data encompasses B2C enterprises. Figures are based on companies' revenues, international institutes data, and global consumer survey data. Revenues refer to the retail value and include sales taxes.

Modeling approach / Market size:

Market sizes are determined by a combined top-down and bottom-up approach, based on a specific rationale for each market market. As a basis for evaluating markets, we use financial reports and third-party data. Next, we use relevant key market indicators and data from country-specific associations such as healthcare spending per capita, medical product spending per capita, and gross domestic product per capita. This data helps us to estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, S-Curve function, ARIMA time series model and exponential curve function. Data is modeled using current exchange rates.

Additional Notes:

The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. GCS data is reweighted for representativeness.

This report presents a comprehensive analysis and additional information on the Health market, in a PDF format.

Despite what some may think, mental health problems are common in the United States and around the world. Mental health issues, much like other health issues, can be mild, but can also be life altering, affecting the emotional, social, and psychological well-being of the person. Common types of mental illness include mood disorders, anxiety disorders, eating disorders, and personality disorders. Although symptoms of mental illness differ depending on the type of illness and seriousness of the problem, common symptoms of mental health issues include changes in sleeping and eating habits, social withdrawal, feelings of hopelessness, anger, and prolonged sadness, suicidal thoughts, and substance abuse. In 2022, it was estimated that around 36 percent of those in the U.S. aged 18 to 25 years and 29 percent of those aged 26 to 49 years suffered from some form of mental illness in the past year.